PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis

This report provides detailed information on the global seasonal influenza market.
Spread the Word
Listed Under

* PharmaPoint
* Influenza Vaccines
* Pharmaceuticals_and_healthcare

* Health

* London, Greater - England

Nov. 30, 2012 - PRLog -- In a mature market with fierce competition, firms operating in the seasonal influenza vaccine industry are increasingly focused on developing products for the high-risk, but underserved, patient pools of the elderly and children under two years of age, finds healthcare industry experts GlobalData in a new report.

The firm’s latest report* says that the main drivers of the global market over the next decade will be an increased focus on the production of treatments for these vulnerable populations by introducing quadrivalent vaccines and vaccines with a better route of administration.

In a bid to tap into this burgeoning sector, pharmaceutical giant Sanofi recently released Fluzone High-Dose – a vaccine specifically designed to have improved efficacy in elderly patients. Fluad, an adjuvanted vaccine from Swiss multinational firm Novartis, is currently undergoing FDA review for approval in the US market. AstraZeneca’s intranasal influenza vaccine, FluMist, enters the EU market in 2012.

According to GlobalData, flu vaccines currently on the market have satisfactory efficacy for most individuals, but achieving adequate vaccination coverage in most countries remains a problem. With varying levels of healthcare and reimbursement infrastructure, patients in emerging markets are at a distinct disadvantage compared to patients from Western countries, such as the US and Europe.

For Sample Pages, please click or add the below link to your browser:

GlobalData’s report also states that despite a crowded field of competitors, there still remains the opportunity for new vaccines with novel routes of administration, innovative methods of production (i.e., cell culture- or recombinant-based), or enhanced efficacy in elderly patients to take a slice of a multi-billion dollar global market.

From a 2012 estimated valuation of US$2.4 billion, the global seasonal influenza vaccines market is predicted to reach US$3 billion by 2022.

By 2022, the US is expected to generate the largest revenue with 47% of the total market, while Japan is predicted to be second with a 14% share. The top 5 EU markets are forecast to hold 16%, while the combined markets of India and China will make up the remaining 13%.In 2011, the share of gas in the US power mix was a little over 41%, but while natural gas energy production will continue to grow, its share in the national power mix is expected to fall by 1.6% by 2020, thanks in vvldt no small part to government initiated renewable energy initiatives.

This report provides detailed information on the global seasonal influenza market.

For further details, please click or add the below link to your browser:

Visit our report store:

For more details

North America:          +1 646 395 5477

Europe:          +44 207 753 4299

         +44 1204 543 533
Asia Pacific:          +91 40 6616 6782
Email:*** Email Verified
Zip:EC4Y 0AN
Tags:PharmaPoint, Influenza Vaccines, Pharmaceuticals_and_healthcare
Location:London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
GlobalData News
Daily News
Weekly News

Like PRLog?
Click to Share